Survival analysis of intrahepatic arterial infusion of Endostar combined with transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma
-
摘要:
目的探讨恩度肝动脉灌注联合经导管肝动脉化疗栓塞治疗中晚期肝癌的疗效。方法选取2009年9月-2011年6月天津医科大学附属石油医院收治的76例中晚期肝癌患者。其中44例给予恩度肝动脉灌注联合经导管肝动脉化疗栓塞治疗,其余32例作为对照组,仅行经导管肝动脉化疗栓塞治疗。治疗后,所有患者不定期行CT或磁共振成像(MRI)检查,观察肿瘤复发或转移情况以及有无肿瘤新生血管形成。计数资料组间比较采用χ2检验,Kaplan-Meier法绘制生存曲线,Log-rank法分析两组术后生存差异。结果恩度治疗组的治疗有效率(RR)高于对照组(70.45%vs 43.75%),差异有统计学意义(χ2=5.47,P<0.05);疾病控制率(DCR)高于对照组(84.09%vs 56.25%),差异有统计学意义(χ2=7.18,P<0.01);两组中位无进展生存时间(m PFS)分别为9.00个月和5.00个月,差异有统计学意义(P=0.044)。中位生存期(m OS)分别为10.64个月和8.11个月,差异无统计学意义(P=0.448)。结论采用恩度肝动脉灌注联合经导管肝动脉化疗栓塞治疗中晚期肝癌...
-
关键词:
- 肝肿瘤 /
- 内皮抑素类 /
- 化学疗法,肿瘤,局部灌注 /
- 化学栓塞,治疗性
Abstract:Objective To assess the efficacy of intrahepatic arterial infusion of Endostar( rh- endostatin,YH- 16) combined with transcatheter arterial chemoembolization( TACE) for the treatment of advanced hepatocellular carcinoma( a HCC). Methods The study enrolled 76 a HCC patients who were admitted to and treated at the Petroleum Hospital Affiliated to Tianjin Medical University during September2009 to June 2011. Of these,44 patients were treated with TACE plus Endostar,and the other 32( the control group) with TACE alone.After treatment,all patients were subjected to non- scheduled re- examination by computed tomography( or magnetic resonance imaging),in order to check tumor recurrence( or metastasis) and angiogenesis. Count data were compared between groups using the χ2test. Survival curves were plotted using the Kaplan- Meier method,and postoperative survival differences were analyzed using the log- rank test. Results Compared with the control group,the experimental group treated with TACE plus Endostar had significantly increased response rate( 70. 45% vs. 43. 75%,χ2= 5. 47,P < 0. 05) and disease control rate( 84. 09% vs. 56. 25%,χ2= 7. 18,P < 0. 01). The median progression- free survival significantly differed between groups( 9. 00 vs. 5. 00 months,P = 0. 044),whereas the median overall survival showed no significant difference( 10. 64 vs. 8. 11 months,P = 0. 448). Conclusion TACE plus Endostar significantly improves the short- term outcome and progression- free survival but has little effect on the overall survival span in patients with a HCC.
计量
- 文章访问数: 2284
- HTML全文浏览量: 14
- PDF下载量: 562
- 被引次数: 0